A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Chronic, Non-Malignant Pain
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27612
- PRA International
-
Raleigh, North Carolina, United States, 27612
- PRA, Intl.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- History of chronic non-malignant pain (originating from a non-malignant source) with condition(s) underlying the chronic pain of greater than or equal to (≥) 2 months' duration before the screening visit.
- Taking oral, transdermal, intravenous (IV), or subcutaneous (SC) opioids for chronic non-malignant pain for ≥1 month.
- No known history of chronic constipation prior to the initiation of opioid therapy.
- Currently taking laxative therapy for ≥30 days and willing to discontinue all laxative therapy at the start of screening period and use only study-permitted rescue laxatives throughout the screening and double-blind treatment periods..
Key Exclusion Criteria:
- Prior treatment with oral MNTX.
- Prior treatment with SC MNTX within 30 days of screening.
- Women who are pregnant, breastfeeding, or plan to become pregnant during the study.
- Fecal incontinence, rectal prolapse, fecal ostomy or other clinically significant gastrointestinal disorders such as inflammatory bowel disease or clinically significant irritable bowel syndrome that would have made bowel movement assessment inaccurate.
- Current treatment with partial opioid agonists (for example; buprenorphine) or combination agonists/antagonists.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: MNTX 150 mg
Participants will receive methylnaltrexone (MNTX) 150 milligrams (mg) (1 tablet of MNTX 150 mg and 2 matching placebo tablets) orally once daily (QD) for 28 days (4 weeks), then MNTX tablets at a dose as needed (PRN) for remaining 56 days (8 weeks).
|
Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
Other Names:
Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.
|
|
EXPERIMENTAL: MNTX 300 mg
Participants will receive MNTX 300 mg (2 tablets of MNTX 150 mg each and 1 matching placebo tablet) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).
|
Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
Other Names:
Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.
|
|
EXPERIMENTAL: MNTX 450 mg
Participants will receive MNTX 450 mg (3 tablets of MNTX 150 mg each) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).
|
Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
Other Names:
|
|
PLACEBO_COMPARATOR: Placebo
Participants will receive 3 tablets of placebo matched to MNTX orally QD for 84 days (12 weeks).
|
Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Average Percentage of Dosing Days That Resulted in Rescue-Free Bowel Movements (RFBMs) Within 4 Hours of Dosing During Weeks 1 to 4
Time Frame: Weeks 1 to 4
|
RFBM was defined as a bowel movement without laxative use within 24 hours prior to bowel movement.
|
Weeks 1 to 4
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Who Responded (Responder) to Study Drug During Weeks 1 to 4
Time Frame: Weeks 1 to 4
|
A responder was defined as at least 3 RFBMs/week, with an increase of at least 1 RFBM/week over baseline, for at least 3 out of the first 4 weeks of the treatment period.
Weekly number of RFBMs were calculated as follows: 7 * total number of RFBMs in a week/all non-missing assessment days in the given week.
Weekly number of RFBMs was set to missing for any week when a participant completed less than (<) 4 diary days in a week.
A RFBM was a bowel movement without laxative use within 24 hrs prior to the bowel movement.
|
Weeks 1 to 4
|
|
Change in Weekly Number of RFBMs From Baseline Over the Entire First 4 Weeks (28 Days) of Dosing
Time Frame: Baseline, Weeks 1 to 4
|
Weekly number of RFBMs were calculated as follows: 7 * total number of RFBMs in a week/all non-missing assessment days in the given week.
Weekly number of RFBMs was set to missing for any week when a participant completed less than (<) 4 diary days in a week.
A RFBM was a bowel movement without laxative use within 24 hrs prior to the bowel movement.
|
Baseline, Weeks 1 to 4
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MNTX 3201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.